{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T23:57:55Z","timestamp":1791071875815,"version":"4.1.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[1994,11,1]],"date-time":"1994-11-01T00:00:00Z","timestamp":783648000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[1994,11,1]],"date-time":"1994-11-01T00:00:00Z","timestamp":783648000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[1994,11]]},"DOI":"10.1136\/ard.53.11.776","type":"journal-article","created":{"date-parts":[[2008,7,28]],"date-time":"2008-07-28T23:49:46Z","timestamp":1217288986000},"page":"776-779","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Increased mitogenic activity of scleroderma serum: inhibitory effect of human recombinant interferon-gamma."],"prefix":"10.1016","volume":"53","author":[{"given":"M","family":"Bryckaert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Fontenay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Liot\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Bellucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Carriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Tobelem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1084\/jem.149.6.1326","article-title":"Endothelial injury in scleroderma","volume":"149","author":"B, Kahaleh M.; K, Sherer G.; C, LeRoy E.","year":"1979","unstructured":"Kahaleh M B, Sherer G K, LeRoy E C. Endothelial injury in scleroderma. J Exp Med 1979; 149: 1326-35.","journal-title":"J Exp Med"},{"key":"ref_2","first-page":"553","article-title":"Endothelial injury in scleroderma. A protease mechanism","volume":"101","author":"B, Kahaleh M.; C, LeRoy E.","year":"1983","unstructured":"Kahaleh M B, LeRoy E C. Endothelial injury in scleroderma. A protease mechanism. J Lab Clin Med 1983; 101: 553-60.","journal-title":"J Lab Clin Med"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/art.1780260208","article-title":"Cytotoxicity of sera from patients with scleroderma. Effects on human endothelial cells and fibroblasts in culture","volume":"26","author":"Cohen, S.; R, Johnson A.; Hurd, E.","year":"1983","unstructured":"Cohen S, Johnson A R, Hurd E. Cytotoxicity of sera from patients with scleroderma. Effects on human endothelial cells and fibroblasts in culture. Arthritis Rheum 1983; 26: 170-8.","journal-title":"Arthritis Rheum"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1042\/bj2470597","article-title":"Transforming growth factor (TGF 1() causes a persistent increase in steady state amounts of type I and type III collagen and fibronectin mRNA in normal human dermal fibroblasts","volume":"247","author":"Varga, J.; Rosenbloom, J.; A, Jimenez S.","year":"1987","unstructured":"Varga J, Rosenbloom J, Jimenez S A. Transforming growth factor (TGF 1() causes a persistent increase in steady state amounts of type I and type III collagen and fibronectin mRNA in normal human dermal fibroblasts. Biochemj7 1987; 247: 597-604.","journal-title":"Biochemj7"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/BF00562744","article-title":"Fibroblasts from a patient with scleroderma reveal abnormal metabolism","volume":"259","author":"Krieg, T.; Muller, K.; Goetz, G.","year":"1977","unstructured":"Krieg T, Muller K, Goetz G. Fibroblasts from a patient with scleroderma reveal abnormal metabolism. Arch Dermatol Res 1977; 259: 105-7.","journal-title":"Arch Dermatol Res"},{"key":"ref_6","first-page":"301","article-title":"Immunohistologic demonstration of platelet-derived growth factor (PDGF) and sis-oncogene expression in scleroderma. Invest Derm _l","volume":"92","author":"Gay, S.; E, Jones R.; Huang, G.; E, Gay R.","year":"1989","unstructured":"Gay S, Jones R E, Huang G, Gay R E. Immunohistologic demonstration of platelet-derived growth factor (PDGF) and sis-oncogene expression in scleroderma. Invest Derm _l 1989;92: 301-3."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/rheumatology\/32.11.966","article-title":"Immunoassay of platelet-derived growth factor in the plasma of patients with scleroderma","volume":"32","author":"R, Dunbar P.; A, Harrison; M, Corkill M.; J, Neale T.","year":"1993","unstructured":"Dunbar P R, Harrison A, Corkill M M, Neale T J. Immunoassay of platelet-derived growth factor in the plasma of patients with scleroderma. BrJr Rheum 1993; 32: 966-71.","journal-title":"BrJr Rheum"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1002\/art.1780331011","article-title":"Increased expression of platelet-derived growth factor type, B receptors in the skin of patients with systemic sclerosis","volume":"33","author":"Klareskog, L.; Gustafsson, R.; Sheynius, A.; Hallgren, R.","year":"1990","unstructured":"Klareskog L, Gustafsson R, Sheynius A, Hallgren R. Increased expression of platelet-derived growth factor type,B receptors in the skin of patients with systemic sclerosis. Arthritis Rheum 1990; 33: 1534-41.","journal-title":"Arthritis Rheum"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/jcp.1041340310","article-title":"Recombinant interferon inhibits the mitogenic effect of platelet-derived growth factor at a level distal to the growth factor receptor","volume":"134","author":"Hosang, M.","year":"1988","unstructured":"Hosang M. Recombinant interferon inhibits the mitogenic effect of platelet-derived growth factor at a level distal to the growth factor receptor. Cell Physiol 1988; 134: 396-404.","journal-title":"Cell Physiol"},{"key":"ref_10","first-page":"45","article-title":"Interferon-ot and interferon-y reduce excessive collagen synthesis and procollagen mRNA levels of scleroderma fibroblasts in culture","volume":"968","author":"M, Kahari V.; J, Heino; T, Vuorio; E, Vuorio","year":"1988","unstructured":"Kahari V M, Heino J, Vuorio T, Vuorio E. Interferon-ot and interferon-y reduce excessive collagen synthesis and procollagen mRNA levels of scleroderma fibroblasts in culture. Biochitmt BiophysActa 1988; 968: 45-50.","journal-title":"Biochitmt BiophysActa"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/art.1780290706","article-title":"Inhibition of excessive scleroderma fibroblast collagen production by recombinant interferon","volume":"29","author":"Rosenbloom, J.; Feldman, G.; Freundlich, B.; Jimenez, S.","year":"1986","unstructured":"Rosenbloom J, Feldman G, Freundlich B, Jimenez S. Inhibition of excessive scleroderma fibroblast collagen production by recombinant interferon. Arthritis Rheumi 1986;29: 851-6.","journal-title":"Arthritis Rheumi"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/art.1780230510","article-title":"Preliminary criteria for the classification of systemic sclerosis (scleroderma)","volume":"23","author":"T, Masi A.; P, Rodnan G.; A, Jr, Medsger T.","year":"1980","unstructured":"Masi A T, Rodnan G P, Medsger T A Jr, et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90.","journal-title":"Arthritis Rheum"},{"key":"ref_13","first-page":"1","article-title":"Increased plasma levels of platelet-derived growth factor activity in patients with","volume-title":"progressive systemic sclerosis. Proc Soc Exp Biol Med","volume":"191","author":"Pandolfi, A.; Florita, M.; Altomare, G.; Pigatto, P.; B, Donati M.; Poggi, A.","year":"1989","unstructured":"Pandolfi A, Florita M, Altomare G, Pigatto P, Donati M B, Poggi A. Increased plasma levels of platelet-derived growth factor activity in patients with progressive systemic sclerosis. Proc Soc Exp Biol Med 1989; 191: 1-4."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0002-9343(89)80150-0","article-title":"Recombinant interferon in the treatment of systemic sclerosis","volume":"87","author":"Kahan, A.; Amor, B.; J, Menkes C.; Strauch, G.","year":"1989","unstructured":"Kahan A, Amor B, Menkes C J, Strauch G. Recombinant interferon in the treatment of systemic sclerosis. Am t Med 1989; 87: 273-7.","journal-title":"Am t Med"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1093\/rheumatology\/31.10.683","article-title":"and the UK Systemic Sclerosis Study Group. Alpha interferon2a(Roferon-A) in the treatment of diffuse cutaneous systemic sclerosis: a pilot study","volume":"31","author":"Stevens, W.; Vancheeswaran, R.; M, Black C.","year":"1992","unstructured":"Stevens W, Vancheeswaran R, Black C M, and the UK Systemic Sclerosis Study Group. Alpha interferon2a(Roferon-A) in the treatment of diffuse cutaneous systemic sclerosis: a pilot study. BrJ Rheumatol 1992; 31: 683-9.","journal-title":"BrJ Rheumatol"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724404305?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724404305?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.53.11.776","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T11:36:19Z","timestamp":1737545779000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724404305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1994,11]]},"references-count":15,"journal-issue":{"issue":"11","published-print":{"date-parts":[[1994,11]]}},"alternative-id":["S0003496724404305"],"URL":"https:\/\/doi.org\/10.1136\/ard.53.11.776","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[1994,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Increased mitogenic activity of scleroderma serum: inhibitory effect of human recombinant interferon-gamma.","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.53.11.776","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 1994 \u00a9 THE AUTHORS. Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology, EULAR. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}